The effects of high-dose heparin on inflammatory and coagulation parameters following cardiopulmonary bypass

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 5, 2005, Pages 323-328

  Paparella, Domenico ^a,b   Al Radi, Osman O ^c   Meng, Qing H ^a   Venner, Thomas ^a   Teoh, Kevin ^a   Young, Edward ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cardiac surgery; Cardiopulmonary bypass; Coagulation; Heparin; Inflammation; Platelet; Thrombin

Indexed keywords

CYTOKINE; HEPARIN; INTERLEUKIN 6; PROTAMINE; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE FACTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MALE; PARAMETER; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION;

EID: 22444444742     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000172328.58506.4a     Document Type: Article

References (30)

1. Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothor Surg 2002; 21:232-244.
2. Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, et al. Tumor necrosis factor-alpha and inteleukin-1beta synergistically depress human myocardial function. Crit Care Med 1999; 27:1309-1318.
3. Meldrum DR, Donnahoo KK. Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. J Surg Res 1999; 85:185-199.
4. Liebold A, Keyl C, Birnbaum DE. The heart produces but the lungs consume proinflammatory cytokines following cardiopulmonary bypass. Eur J Cardiothorac Surg 1999; 15:340-345.
5. Young E, Prins M, Levine MN, Hirs J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67:639-643.
6. Young E, Podor TJ, Venner T, Hirsh J. Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vasc Biol 1997; 17:1568-1574.
7. Despotis GJ, Joist JH. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update. J Cardiothorac Vasc Anesth 1999; 13(4 suppl 1):18-29.
8. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost 1993; 70:259-262.
9. Tyrrel DJ, Home AP, Holme KR, Preuss JM, Page CP. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999; 46:151-208.
10. Nelson RM, Cecconi O, Roberts GW, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82:3253-3258.
11. Karlheinz P, Schwarz M, Conradt C, Nordt T, Moser M, Kubler W, et al. Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11/ CD18). Circulation 1999; 100:1533-1539.
12. Lever R, Hoult JR, Page CP. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leukocytes to vascular endothelium in vitro. Br J Pharmacol 2000; 129:533-540.
13. Attanasio M, Gori AM, Giusti B, Pepe G, Comeglio P, Brunelli T, et al. Cytokine gene expression in human LPS- and IFN-γ-stimulated mononuclear cells is inhibited by heparin. Thromb Haemost 1998; 79:959-962.
14. Hoffmann JN, Hartl WH, Faist E, Jochum M, Inthorn D. Tumor necrosis factor measurement and use of different anticoagulants: possible interference in plasma samples and supernatants from endotoxin-stimulated monocytes. Inflamm Res 1997; 46:342-347.
15. 2-macroglobulin. Clin Exp Allergy 1998; 28:616-624.
16. Kouretas PC, Myers AH, Kim YD, Cahill PA, Myers JL, Wang JV, et al. Heparin and nonanticoagulant heparin preserve regional myocardial contractility after ischemia-reperfusion injury: role of nitric oxide. J Thorac Cardiovasc Surg 1998; 115:440-448.
17. Kouretas PC, Kim YD, Cahill PA, Myers AK, To LN, Wang YN, et al. Nonanticoagulant heparin prevents coronary endothelial dysfunction after brief ischemia-reperfusion injury in dog. Circulation 1999; 99:1062-1068.
18. Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993; 329:90-95.
19. Bannan S, Danby A, Cowan D, Ashraf S, Gesinde M, Martin P. Cell activation and thrombin generation in heparin bonded cardiopulmonary bypass circuits using a novel in vitro model. Eur J Cardiothorac Surg 1997; 12:268-275.
20. Ranucci M, Mazzucco A, Pessotto R, Grillone G, Casati V, Porreca L, et al. Heparin-coated circuits for high risk patients: a multicenter, prospective, randomized trial. Ann Thorac Surg 1999; 67:994-1000.
21. Despotis GJ, Joist HJ, Hogue CW Jr, Alsoufiev A, Joiner-Maier D, Santoro SA, et al. More efective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentration rather than ACT. Thromb Haemost 1996; 76:902-908.
22. Khuri SF, Valeri RC, Loscalzo J, Weinstein MJ, Birjiniuk V, Healey NA, et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995; 60:1008-1014.
23. Teoh KH, Bradley CA, Gauldie J, Burrows H. Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery. Circulation 1995; 92(9suppl):II347-II353.
24. Roth-Isigkeit A, Borstel T, Seyfarth M, Schmucker P. Perioperative serum levels of tumor necrosis alpha (TNF-α), IL-1β, IL-6, IL-10 and soluble IL2 receptor in patients undergoing cardiac surgery without or with correction for haemodilution. Clin Exp Immunol 1999; 118:242-246.
25. Koster A, Fischer T, Praus M, Haberzettl H, Kuebler W, Hetzer R, et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass. Impact of heparin management. Anesthesiology 2002; 97:837-841.
26. Kestin AS, Valeri CR, Khuri SF, Loscalzo J, Ellis PA, MacGregor H, et al. The platelet function defect of cardiopulmonary bypass. Blood 1993; 82:107-117.
27. Muriithi EW, Belcher PR, Day SP, Menys VC, Wheatley DJ. Heparin induced platelet dysfunction and cardiopulmonary bypass. Ann Thorac Surg 2000; 69:1827-1832.
28. Muriithi EW, Belcher PR, Day SP, Chaudhry MA, Caslake MJ, Wheatley DJ. Lipolysis generates platelet dysfunction after in vivo heparin administration. Clin Sci (Lond) 2002; 103:433-440.
29. Nakajima T, Kawazoe K, Ishibashi K, Kubota Y, Sasaki T, Izumoto H, et al. Reduction of heparin dose is not beneficial to platelet function. Ann Thorac Surg 2000; 70:186-190.
30. Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30:1873-1881.